These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9435855)

  • 21. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor.
    Vasiljevic S; Beale EV; Bonomelli C; Easthope IS; Pritchard LK; Seabright GE; Caputo AT; Scanlan CN; Dalziel M; Crispin M
    Mol Immunol; 2015 Dec; 68(2 Pt A):234-43. PubMed ID: 26391350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody fragments: hope and hype.
    Nelson AL
    MAbs; 2010; 2(1):77-83. PubMed ID: 20093855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies in single-chain format against tumour-associated antigens: present and future applications.
    Accardi L; Di Bonito P
    Curr Med Chem; 2010; 17(17):1730-55. PubMed ID: 20345346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bispecific human IgG by design.
    Carter P
    J Immunol Methods; 2001 Feb; 248(1-2):7-15. PubMed ID: 11223065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
    Wels W; Groner B; Hynes NE
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001
    [No Abstract]   [Full Text] [Related]  

  • 29. Structure and thermodynamics of antigen recognition by antibodies.
    Braden BC; Cauerhff A; Dall'Acqua W; Fields BA; Goldbaum FA; Malchiodi EL; Mariuzza RA; Poljak RJ; Schwarz FP; Ysern X
    Ann N Y Acad Sci; 1995 Sep; 764():315-27. PubMed ID: 7486542
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapeutic antibodies and related products: choosing the right structure for success].
    Beck A; Wagner-Rousset E; Wurch T; Corvaia N
    Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nature's design: A blueprint for engineered therapeutic antibodies.
    Rodeck U; Williams JC
    Cancer Biol Ther; 2008 Nov; 7(11):1751-2. PubMed ID: 18981729
    [No Abstract]   [Full Text] [Related]  

  • 32. Potential therapeutic roles for antibody mixtures.
    Raju TS; Strohl WR
    Expert Opin Biol Ther; 2013 Oct; 13(10):1347-52. PubMed ID: 23886377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular and cell surface displayed single-chain diabodies.
    Kontermann RE; Müller R
    J Immunol Methods; 1999 Jun; 226(1-2):179-88. PubMed ID: 10410983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
    Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
    Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bispecific antibodies: what future?].
    Pèlegrin A; Robert B
    Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-chain antibodies as diagnostic tools and therapeutic agents.
    Hagemeyer CE; von Zur Muhlen C; von Elverfeldt D; Peter K
    Thromb Haemost; 2009 Jun; 101(6):1012-9. PubMed ID: 19492141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation and characterization of bispecific tandem diabodies for tumor therapy.
    Kipriyanov SM
    Methods Mol Biol; 2003; 207():323-33. PubMed ID: 12412483
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.